EICHOR
● Active Not Recruiting
Study of INBRX-109 in Conventional Chondrosarcoma
Condition: Conventional Chondrosarcoma · Sponsor: Inhibrx Biosciences, Inc
About this study
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (68)
| Mayo Clinic Cancer Center | Phoenix, Arizona, United States | — |
| Precision NextGen Oncology & Research Center | Beverly Hills, California, United States | — |
| University of California, San Francisco (UCSF) | San Francisco, California, United States | — |
| Sarcoma Oncology Center | Santa Monica, California, United States | — |
| University of Colorado | Denver, Colorado, United States | — |
| Yale Cancer Center | New Haven, Connecticut, United States | — |
| Mayo Clinic - Jacksonville | Jacksonville, Florida, United States | — |
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| Northwestern University - Robert H. Lurie Comprehensive Cancer Center | Chicago, Illinois, United States | — |
| Rush Cancer Center | Chicago, Illinois, United States | — |
| University of Iowa | Iowa City, Iowa, United States | — |
| Johns Hopkins | Baltimore, Maryland, United States | — |
+ 56 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04950075